Avadel Pharmaceuticals Management
Management criteria checks 2/4
Avadel Pharmaceuticals' CEO is Greg Divis, appointed in Jan 2019, has a tenure of 6.58 years. total yearly compensation is $7.40M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $4.75M. The average tenure of the management team and the board of directors is 5.2 years and 7.1 years respectively.
Key information
Greg Divis
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 8.81% |
| CEO tenure | 7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 5.2yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Oct 23Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Aug 02Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jun 10
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
May 04Avadel Pharmaceuticals: Moving To A Speculative Buy
Feb 11The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Feb 07Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jan 13The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$278k |
| Jun 30 2025 | n/a | n/a | -US$3m |
| Mar 31 2025 | n/a | n/a | -US$26m |
| Dec 31 2024 | US$7m | US$652k | -US$49m |
| Sep 30 2024 | n/a | n/a | -US$73m |
| Jun 30 2024 | n/a | n/a | -US$106m |
| Mar 31 2024 | n/a | n/a | -US$157m |
| Dec 31 2023 | US$985k | US$600k | -US$160m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$142m |
| Dec 31 2022 | US$754k | US$561k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$90m |
| Dec 31 2021 | US$3m | US$545k | -US$77m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$3m | US$520k | US$7m |
| Sep 30 2020 | n/a | n/a | US$16m |
| Jun 30 2020 | n/a | n/a | US$18m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$472k | -US$33m |
Compensation vs Market: Greg's total compensation ($USD7.40M) is above average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
CEO
Greg Divis (58 yo)
Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since June 2019. Mr. Divis served as an Interim Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$7.40m | 0.23% $ 4.8m | |
| Senior VP | 6.1yrs | US$2.29m | 0.089% $ 1.9m | |
| General Counsel | 5.3yrs | US$2.04m | 0.0090% $ 189.1k | |
| Chief Operating Officer | 1.7yrs | no data | no data | |
| VP of Corporate and Business Development | 10.5yrs | no data | 0.17% $ 3.6m | |
| Vice President of People & Culture | 4.7yrs | no data | no data | |
| Senior Vice President of Technical Operations | 6.1yrs | no data | no data | |
| Senior Vice President of Medical & Clinical Affairs | 5.1yrs | no data | no data | |
| Chief Business Officer | 1.7yrs | no data | no data | |
| Senior Vice President of Regulatory & Quality | 1.7yrs | no data | no data |
Experienced Management: AVDL's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$7.40m | 0.23% $ 4.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$394.48k | 0.079% $ 1.7m | |
| Independent Director | 1.7yrs | US$1.01m | 0.011% $ 236.6k | |
| Independent Director | 8.6yrs | US$404.48k | 0.11% $ 2.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.1yrs | US$396.98k | 0.21% $ 4.5m | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman of the Board | 7.5yrs | US$426.98k | 0.16% $ 3.4m | |
| Independent Director | 7.5yrs | US$634.50k | 0.069% $ 1.5m |
Experienced Board: AVDL's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 13:19 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avadel Pharmaceuticals plc is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |